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Exon-specific U1 snRNAs (ExSpe U1s) are modified U1 snRNAs that interact with intronic sequences downstream of the 50 splice site (ss)
by complementarity. This process restores exon skipping caused by different types of mutation. We have investigated the molecular
mechanism and activity of these molecules in spinal muscular atrophy (SMA), a genetic neuromuscular disease where a silent exonic
transition on the survival motor neuron 2 (SMN2) leads to exon 7 (E7) skipping. By using different cellular models, we show that a single
chromosome-integrated copy of ExSpe U1 induced a significant correction of endogenous SMN2 E7 splicing and resulted in the restora-
tion of the corresponding SMN protein levels. Interestingly, the analysis of pre-mRNA transcript abundance and decay showed that Ex-
Spe U1s promote E7 inclusion and stabilizes the SMN pre-mRNA intermediate. This selective effect on pre-mRNA stability resulted in
higher levels of SMNmRNAs in comparisonwith those after treatment with an antisense oligonucleotide (AON) that targets correspond-
ing intronic sequences. Inmice harboring the SMN2 transgene, AAV-mediated delivery of ExSpe U1 increased E7 inclusion in brain, heart,
liver, kidney, and skeletal muscle. The positive effect of ExSpe U1s on SMN pre-mRNA processing highlights their therapeutic potential
in SMA and in other pathologies caused by exon-skipping mutations.Introduction
Pre-mRNA splicing is a finely regulated process that requires
specific signals onRNAmolecules, suchas the50 and30 splice
sites (50 ss and 30 ss), the branch point sequence (BPS), and
additional less-conserved intronic or exonic elements with
enhancer or silencer functions (ISE, ESE, ISS, ESS, respec-
tively).1,2 These elements drive the spliceosome, themacro-
molecular complex that catalyzes the splicing reaction, in
the identification of the correct exon-intron boundaries
among the never-used pseudo-splice sites located in the
pre-mRNA molecules.3 The first step of spliceosome assem-
bly involves the bindingof theU1 small nuclear ribonucleo-
particle (U1 snRNP) to the 50 ss of an exon through its 9-bp-
long50 tail.4U1 snRNAshave a stable anddefined secondary
structure that interacts with a set of U1-specific proteins
named U1-A, U1-70K, and U1-C as well as with the Smith
antigen (Sm) proteins, common to all U-rich snRNAs.5
These interactions result in the formation of a functional
U1 snRNP. Recently, the biological repertoire of the U1 par-
ticle has expanded, because its involvement in different
cellular processes beyond splicing has been demon-
strated.6 In particular, U1 snRNPs protect transcripts from
premature cleavage andpolyadenylation at cryptic polyade-
nylation signals (PASs) in introns and, when positioned on
the first exon, promote transcription.7–9
A large proportion of disease-causing mutations has
been shown to affect the splicing mechanism, mainly
causing the skipping of an exon from the final tran-
script.10,11 We recently developed an approach to correct
exon skipping based on modified U1 snRNAs, named
exon-specific U1s (ExSpe U1s).12 Differently from previ-
ously reported modified-U1-based approaches aimed at re-1Human Molecular Genetics Laboratory, International Centre for Genetic Eng
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The Aminforcing the binding of the U1 particle at suboptimal
50 ss,13–16 ExSpe U1s have engineered 50 tails that direct
their loading onto nonconserved intronic regions down-
stream of the donor site of a specific exon, reducing unde-
sired off-target events. We previously demonstrated that a
number of different ExSpe U1s are able to correct aberrant
splicing resulting from different types of mutations inmin-
igene models of Coagulation Factor IX, CFTR, and SMN2.12
To characterize the activity of ExSpe U1s and to further
investigate their mechanism of action in vivo, in the pre-
sent work we focused on spinal muscular atrophy (SMA
[MIM 253300]). SMA is a recessive-autosomal neuromus-
cular disease affecting a-motoneurons in the anterior
horn of the spinal cord. It is a leading genetic cause of in-
fant mortality, with a carrier frequency of ~1:35 and an
incidence of ~1:6,000 newborns. SMA clinical symptoms
appear in childhood, are of variable severity, and comprise
progressive muscular weakness and atrophy that affect
mainly proximal muscles.17 There is currently no treat-
ment for this pathology. SMA is caused by a homozygous
loss of function of survival motor neuron (SMN1 [MIM
600354]), which encodes for SMN, a key protein in the
biogenesis of small ribonucleoparticles (snRNPs), which
has recently been associated with a complex system of
neuronal circuitry18–20 and has also been linked to tran-
scription, stress response, apoptosis, axonal transport,
and cytoskeletal dynamics.21–23 However, humans possess
a SMN1 paralog, named SMN2 (MIM 601627), located as
well on chromosome 5, but in centromeric position. The
coding sequence of the paralog gene is nearly identical to
SMN1, with the exception of a silent exonic cytosine-to-
thymine (C-T) transition at nucleotide 840, matching the
position þ6 of exon 7 (E7). This substitution disrupts anineering and Biotechnology (ICGEB), Padriciano 99, 34149 Trieste, Italy
s.org/licenses/by/3.0/).
erican Journal of Human Genetics 96, 93–103, January 8, 2015 93
SRSF1-dependent exonic splicing enhancer (ESE)24–26 and
creates an intronic splicing silencer (ISS) recognized by
the inhibitory splicing factor hnRNPA1.27 As a conse-
quence, the majority of SMN2 mRNAs lack E7 and lead to
the formation of a truncated, highly unstable DE7 protein,
which rapidly undergoes degradation.28 The small amount
of full-length (FL) protein produced by SMN2 is therefore
essential for survival, and the number of copies of SMN2
inversely correlate with the severity of the pathology.17
Although SMA is not a splicing disease per se, SMN2 is an
optimum candidate for a splicing therapy, because all
SMA-affected individuals retain at least two copies of
SMN2. Correction of E7 missplicing can be obtained
through antisense masking of an hnRNPA1-dependent in-
tronic splicing silencer N1 (ISS-N1) located downstream of
the E7 donor splice site via chemically modified antisense
oligonucleotides (AONs) or modified U7 snRNAs.17,29 In
addition, a compound has been recently described that
selectively enhances SMN transcripts.30 The ISS-N1 com-
prises a 15-bp-long intronic sequence located downstream
of E7 50 ss, spanning from position þ10 to þ24. Mutagen-
esis and binding experiments showed the presence of two
weak cooperative binding sites for the inhibitory splicing
factor hnRNPA1 that recognizes the CAG and AAAGmotifs
present in the pre-mRNA molecule at positions þ11/þ13
and þ21/þ24, respectively.31 Here we show that three
ExSpe U1s previously reported to be active in SMN2 mini-
gene assays are able to fully reverse E7 aberrant splicing in
fibroblasts from individuals with the severe SMA type I.
Transduction of primary cells from SMA-affected individ-
uals with lentiviral particles expressing SMN-specific ExSpe
U1s restores normal E7 transcript levels, leading to the
production of physiological amounts of functional SMN
protein. Adeno-associated virus (AAV)-mediated delivery
of ExSpe U1 corrects SMN2 splicing in transgenic mice.
Furthermore, we demonstrate that a single chromosome-
integrated copy of SMA-specific ExSpe U1 is sufficient to in-
fluence endogenous SMN1 and SMN2mRNAs by positively
modulating E7 processing through a molecular mecha-
nism that differs from the one previously reported for anti-
sense oligonucleotide 10–27 (AON 10–27) that masks a
pre-mRNA sequence.Material and Methods
Cell Culture and Lentiviral Production
HEK293 Flp-In cells and SMA fibroblasts (G3813, G3814 Coriell
Institute) were grown in Dulbecco’s modified Eagle’s medium
with Glutamax I (GIBCO) (DMEM with glutamine, sodium pyru-
vate, pyridoxine, and 4.5 g/l glucose) supplemented with 10%
fetal calf serum (Euro Clone) and antimycotic (Sigma) according
to the manufacturer’s instruction.
Selection of HEK293 Flp-In stable clones were carried out with
hygromycin and the expression of the gene of interest verified
through specific RT-PCRs.
Lentiviral particles encoding eGFP and U1 snRNAWT or ExSpe
sm2 or sm17 or sm21 were prepared through cotransfection in94 The American Journal of Human Genetics 96, 93–103, January 8, 2HEK293T cells of psPAX vector encoding for gag-pol, tet, and rev
proteins, pVSV-G encoding packaging proteins, and modified
pLVTHMplasmid encoding the greenfluorescent protein (GFP) un-
der the cytomegalovirus (CMV) promoter and U1 snRNA WT or
SMA-specific ExSpe U1 gene under their own promoter. Transfec-
tion efficiency was monitored through GFP evaluation at FACS.
The viral supernatant was collected from transfected cells after
48 hr and concentrated by ultracentrifugation at 25,000 rpm for
90min. The viral pelletwas resuspended in PBS 13 andflash frozen
in liquid nitrogen and aliquots were stored at80C until use. The
titer of the virus we obtained was 43 108 bTU/ml. SMA fibroblasts
were grown on 6-well plates and transduced with 43 106 lentiviral
particles with a multiplicity of infection (MOI) of 15. AON 10–27
was transfected in HEK293 Flp-In cells as previously described.32Administration of scAAV9 to SMN2 Transgenic Mice
Mice were housed and handled according to institutional guide-
lines, and experimental procedures were approved by the Inter-
national Centre for Genetic Engineering and Biotechnology
(ICGEB) board, with full respect to the EU Directive 2010/63/EU
for animal experimentation. A total of 12 SMN2 transgenic mice
(FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd/J; Jackson Laboratories,
stock number 005024), males or females, hemizygote or wild-
type at the Smn locus were divided into three different groups
and tested as follows: four mice were injected intraperitoneally
(i.p.) at postnatal day 1 (P1) with 20 ml of scAAV9-ExSpe sm21 (titer
¼ 2.23 3 1013 VG/ml, SignaGen Laboratories), four mice were
injected with scAAV9-U1 WT (titer ¼ 2 3 1013 VG/ml SignaGen
Laboratories), and four untreated animals were used as controls.
All the 12 mice were sacrificed after 4 weeks. Mouse tissues and or-
gans (brain, heart, kidney, liver, skeletal muscle) were collected,
snap frozen in liquid nitrogen, and stored at 80C. For RNA
extraction, 1 ml of Trizol (Invitrogen) was used to homogenize
100 mg of each tissue. Total RNA was then extracted according
to the manufacturer’s instructions.RT-PCR, Sybr-Green qPCR, and TaqMan Assay
Total RNA was isolated with TRIzol reagent (Invitrogen). Reverse
transcription was performed with random primers via SuperScript
III reverse transcriptase (Invitrogen). Semiquantitative RT-PCR on
SMA type I primary fibroblasts and endogenous HEK293 SMN
transcripts was carried out with 50-FAM-labeled E6-Fw and E8-
467-Rev primers (Table S1 available online). RT-PCR on SMN2
transgene in mice was carried out with a set of human-specific
primers as previously reported.31 RT-PCR after minigene splicing
assay was performed as previously described.12 For HEK293 cells
and SMA fibroblasts, amplified products were digested with DdeI
enzyme to discriminate transcripts coming from SMN1 or SMN2.
The resulting amplified products were run in denaturing capillary
electrophoresis. The peaks resulting from capillary electrophoresis
were analyzed through PeakScanner software and the ratio be-
tween splicing isoforms shown as histograms. The intensity of
the bands in agarose gels was determined with ImageJ software.
For specific detection of ExSpe U1 sm17 and sm21, total RNA
was treated with DNase and RT-PCRs were carried out with
U1sm17-Fw or U1sm21-Fw along with U1-160 Rev (Table S1).
The efficiency (Eff) of the U1 WT, ExSpe U1 sm17, and sm21
qPCR reactions has been calculated by the following equation:
Eff¼ 10(1 / slope) 1. TaqMan Assay on SMN E7 or DE7 was per-
formed as previously described.33 Sybr-green-based quantitative
PCR on SMN total transcripts and SMN exon 2 or exon 7 splicing015
Figure 1. A Single Chromosome-Integrated Copy of ExSpe U1
Improves SMN2 E7 Inclusion in HEK293 Flp-In Stable Clones
(A) Schematic representation of SMN exon 7 pre-mRNA. The dark
box represents the exon. The asterisk indicates the position of the
exonic C-to-U transition in position þ6. The sequence of the
modified 50 tails of the different ExSpe U1s and the target se-
quences on pre-mRNA are indicated. The hnRNPA1-dependent in-
tronic splicing silencer N1 spanning from position þ10 to þ24
(ISS-N1) is shown.
(B) Total RNA extracted from the indicated cells was analyzed by
RT-PCR with E6-F 50-FAM-labeled and E8-467R primers. Amplifica-
tion products were digested with DdeI restriction enzyme and the
resulting fragments run on denaturing capillary electrophoresis
for quantification of SMN1 and SMN2 isoforms. The ratio between
the peaks corresponding to SMN1 or SMN2 spliced isoforms was
calculated with Peak Scanner software. The percentage of exon 7
inclusion is expressed as mean 5 SD of three independent
experiments.intermediates was carried out with Ex2a Fw in combination with
Ex2b Rev, Int1_13850Fw in combination with Int2a_14006 Rev,
and Int6 Fw in combination with Int7 Rev (Table S1).
mRNA Stability Assay
HEK293 Flp-In cells were treated with a-ammannitin (20 mg/ml)
and collected every 5 hr at five different time points (0, 5, 10,
15, and 20 hr). Total RNA was extracted and treated with DNase,
and Sybr-green-based quantitative RT-PCR on SMN total tran-
scripts and SMN E7 splicing intermediates was carried out as re-
ported above. 18S RNAs were used as normalization control with
18S Fw and 18S Rev primers (Table S1).
30 Rapid Amplification of cDNA Ends Assay
Total RNA from HEK293 Flip-In stable clone lines expressing
ExSpe U1 sm2, sm17, sm21, and the U1 snRNAWT was extracted
with TRIzol reagent (Invitrogen). Reverse transcription was per-
formed with oligo dT via SuperScript III reverse transcriptase (Invi-The Amtrogen). 30 RACE PCR was performed with forward primer located
on SMN exon 6, SMN exon 7, or SMN exon 8, and Anchor primer
as reverse (Table S1).Immunoblot
Protein samples separated by NuPAGE 4%–12% Bis-Tris precast
gels (Life Technologies) were electroblotted onto nitrocellulose
membranes. The membrane was probed with monoclonal anti-
SMN (BD Transduction Laboratories) and anti-a-tubulin (courtesy
of Dr. Muro) as normalization control, followed by horseradish-
peroxidase-conjugated rabbit anti-mouse secondary antibody. Pro-
tein signals were detected with SuperSignalWest FemtoMaximum
Sensitive Substrate (Thermo Scientific).Statistical Analysis
The data are expressed as the mean5 SD of different experiments
done in triplicate. Data were compared with one-way ANOVA test.
The p values are indicated in the figures and legends.Results
A Single Copy of ExSpe U1 Increases SMN Exon 7
Inclusion in HEK293 Flp-In Cells
We previously reported three ExSpe U1s, named sm2,
sm17, and sm21, active on SMN2 exon 7 (E7) mini-
gene.12 They bind to 9-bp-long intronic sequences
located 2, 17, and 21 bases downstream of E7 donor
site and partially overlap with the previously described
hnRNPA1-dependent intronic splicing silencer N1 (ISS-
N1),31 which is the target of the antisense oligonucleo-
tide (AON) 10–27 (Figure 1A). To understand the effect
of ExSpe U1s on SMN pre-mRNA processing, we took
advantage of the HEK293 Flp-In system. In these cells,
the insertion of a unique copy of the ExSpe U1s at a spe-
cific FRT chromosomal site allowed us to evaluate their
effect on endogenous SMN E7 pre-mRNA processing
and to perform a reliable comparison between the
different ExSpe U1s. We created HEK293 Flp-In stable
clones expressing ExSpe U1s sm2, sm17, or sm21, as
well as U1 snRNA WT as control. We analyzed at least
three different clones for each group and we did not
observe any significant effect on cell viability and prolif-
eration (Figure S1), suggesting that in these experimental
conditions, ExSpe U1s have no toxic effect on cultured
cells. Total RNAs from stable clones were analyzed by
RT-PCR and the resulting amplified fragments digested
with DdeI restriction enzyme to discriminate between
the splicing products derived from endogenous SMN1
and SMN2. Semiquantitative RT-PCR analysis in stable
clones expressing ExSpe U1s showed a significant in-
crease in the percentage of SMN2 exon 7 inclusion
from ~45% up to ~80%–85% (Figures 1B and S2). The
same level of SMN2 E7 inclusion was obtained with the
AON 10–27 treatment (Figures 1B and S2). As expected,
ExSpe U1 and AON also affected SMN1, inducing an in-
crease in the SMN1 E7 inclusion (Figure 1B). Although
HEK293 cells produce high levels of SMN protein becauseerican Journal of Human Genetics 96, 93–103, January 8, 2015 95
Figure 2. ExSpe U1s Increase SMN Tran-
scripts in HEK293 Flp-In Stable Clones
and Stabilize a Pre-mRNA Splicing Inter-
mediate
(A) Schematic representation of the SMN
mRNAs and pre-mRNA analyzed through
quantitative RT-PCR. Boxes are exons and
lines are introns. The localization of the
primers is indicated with arrows. The spe-
cific probes used for E7 and DE7 TaqMan
assay are indicated with lines.
(B) Total RNA from the indicated cells
was extracted. Total SMN mRNA and
SMN E7 splicing intermediate were evalu-
ated through quantitative sybr-green-
based RT-PCRs, and E7 and DE7 mRNAs
through a specific TaqMan assay. Each
RNA molecule level was set to 1 in
HEK293 Flp-In cells and the variation of
the analyzed mRNAs and pre-mRNA
expressed as fold changes. The results
are expressed as mean 5 SD of three
different experiments performed in tripli-
cate. ***p < 0.001, **p < 0.01; ns, not sig-
nificant. One-way ANOVA test.
(C and D) SMN mRNA and pre-mRNA sta-
bility assay. HEK293 Flp-In cells treated or
not with AON 10–27 and HEK293 Flp-In
sm21 stable clone were treated with
20 mg/ml (0h). Cells were harvested at
four different time points after 5 hr (5h),
10 hr (10h), 15 hr (15h), and 20 hr (20h).
Total RNA was extracted and quantitative
RT-PCR carried out with the primers indi-
cated at the top of each scatter plot.
18S levels were used as normalization
control.
(E) Total RNA was extracted from the indi-
cated cells and exon 2 splicing intermedi-
ate levels evaluated through qRT-PCR as
indicated in the top of the panel. The re-
sults are expressed as mean5 SD of three
different experiments performed in tripli-
cate. ***p < 0.001, **p < 0.01; ns, not sig-
nificant. One-way ANOVA test.
(F) 30-RACE (rapid amplification of cDNA
ends) assay. Total RNA was extracted from
the indicated cells and retrotranscribed
with an oligodT with an anchor. Polyade-
nylated transcripts from SMN were evalu-
ated with Exon-6_Fw primer in combination with Anchor_Rev primer. The amplified fragments were separated on 1.5% agarose gel.
The identity of each band, schematically reported on the right of the gel, has been verified through direct sequencing of PCR products.of the presence of both SMN1 and SMN2, we tried to
detect changes in the SMN protein expression in
HEK293 clones stably expressing ExSpe U1s. Interest-
ingly, immunoblot analysis revealed a small but repro-
ducible effect (~1.3- to 1.4-fold increase) in the level of
SMN protein in HEK293 Flp-In cells expressing ExSpe
U1s (Figure S3). The control stable clone expressing U1
snRNA WT affected neither SMN splicing (Figure 1B)
nor SMN protein (Figure S3).
ExSpe U1s Have Multiple Effects of SMN Pre-mRNA
Processing
Beyond its well-established role in splicing, the U1 snRNP
has been shown to have additional effects on pre-mRNA96 The American Journal of Human Genetics 96, 93–103, January 8, 2processing.7,9,34 Therefore, we consider the possibility
that ExSpe U1 might result in a more complex effect on
SMN processing.
To better unravel the effect of ExSpe U1 on SMN pre-
mRNA processing, we evaluated several SMN transcripts
in a quantitative manner with specific primers. We
analyzed the mature SMN transcripts (total mRNA), tran-
scripts with or without E7 (E7 and DE7 mRNAs, respec-
tively), and the pre-mRNA. This analysis was performed
in ExSpe U1 HEK293 clones and in cells treated with
AON 10–27 (Figure 2A), all showing comparable changes
in the percentage of exon 7 (E7) inclusion (Figure 1B).
Analysis of the expression levels of ExSpe U1s sm17 and
sm21 from the corresponding HEK293 Flp-In stable clones015
showed that both ExSpe U1 sm17 and sm21 are expressed
at the same level, that is ~100 time less in comparison to
the endogenous U1 snRNA level (Figure S4). Interestingly,
in all the stable clones expressing ExSpe U1s, but not in
AON-treated cells, we observed up to a ~3.2-fold increase
in total SMN mRNA (Figure 2A). A more detailed analysis
of the mature transcripts with or without E7 showed that
ExSpe U1s improved both SMN isoforms, with a more
pronounced effect on the E7 isoform (Figure 2B). The E7
mRNA was increased to ~2.5-fold whereas the DE7
increased to ~1.7-fold (Figure 2B). Interestingly, targeting
the ISS with the AON 10–27 did not increase the total
amount of mRNA: in this case, the increased level of E7 iso-
form is associated with a corresponding reduction of the
DE7 isoform (Figure 2B). To better clarify this aspect, we
evaluated the abundance of pre-mRNA transcripts via
primers located in introns across exon 7 and exon 2 (E2).
The SMN E7 pre-mRNA—but not SMN E2 pre-mRNA
(Figure 2E)—is increased ~1.7-fold in ExSpe U1 stable
clones, whereas these pre-mRNAs are not affected in
AON-treated cells. These results suggest that whereas the
AONmodulates splicing decision, ExSpe U1 exerts an addi-
tional effect on SMN pre-mRNA processing, which results
in a general increase in both the SMN mRNAs and E7
pre-mRNA.
To investigate a possible synergic effect of AON and
ExSpe U1, we compared the different SMN transcripts
abundance in the ExSpe U1 sm21 stable clone with and
without the AON 10–27 and in HEK293 Flp-In cells
treated with the antisense oligo. In comparison to the
AON treatment alone, AON and ExSpe U1 together re-
sulted in a significant increase in all SMN transcripts
(Figure 2B, compare AON 10–27 with stable ExSpe
sm21þAON). On the other hand, the AON 10–27þExSpe
U1 treatment showed only a slight change in SMN mRNA
and pre-mRNA in comparison to ExSpe U1 alone. In
addition, the increase of the amount of E7 mRNA at
the expense of the DE7 isoform is more pronounced
in ExSpe U1 sm21 stable cells treated with AON 10–27
in comparison to ExSpe U1 sm21 untreated cells
(Figure 2B, compare stable ExSpe sm21 lanes with stable
ExSpe sm21þAON lanes). These findings suggest that
ExSpe U1 and AON 10–27 cooperate synergically in the
SMN splicing rescue.
Because the increased amount of total SMNmRNAs and
E7 pre-mRNAs in ExSpe U1 stable clones could be due to
increased transcript stability, we decided to block tran-
scription with a-amanitin, a compound that specifically
interferes with RNA polymerase II (RNA PolII). The anal-
ysis was performed on ExSpe U1 sm21 stable clone and
in cells treated with AON 10–27 (Figures 2C and 2D).
Quantitative RT-PCR showed no differences in the mature
SMN transcripts decay rate between untreated cells and
cells treated either with ExSpe U1 or with the AON
(Figure 2B). In contrast, analysis of the SMN E7 pre-
mRNAs showed that ExSpe U1 stable clones had a
~25%–30% lower decay rate in comparison to cells treatedThe Amwith the AON or to normal cells (Figure 2D). In fact, 20 hr
after inhibition of transcription, the ExSpe U1 cells retain
~40% of SMN E7 pre-mRNAs whereas the AON-treated or
normal cells have ~10% (Figure 2D). Thus, ExSpe U1s pro-
mote E7 inclusion and inhibit the decay of the SMN E7
pre-mRNA.
To investigate the possibility that ExSpe U1s might
protect the SMN transcripts from a premature polyadeny-
lation, we performed a 30-RACE. By using a forward primer
located on SMN exon 6, we detected two transcripts—with
and without exon 7—that use a unique polyadenylation
signal (PAS) within exon 8 (Figure 2F). As expected, ExSpe
U1 increases the ratio between E7/DE7 isoforms but did
not affect poly(A) sites. 30-RACE assay with forward
primers on exon 7 or 8 confirmed the usage of the canon-
ical poly(A) site (Figure S5).
ExSpe U1s Replace Endogenous U1 snRNP in SMN
Exon 7 Definition
To further investigate how ExSpe U1 rescues E7 skipping
and facilitates SMN processing, we considered the roles
of the inhibitory splicing factor hnRNPA1 that binds to
the ISS-N1 and of the endogenous U1 snRNP. Both over-
expression of hnRNPA1 and functional suppression of U1
snRNP inhibit SMN2 E7 inclusion.35 We tested in SMN2
E7 minigene the dose-dependent effect of hnRNPA1
overexpression on the rescue efficiency mediated by
ExSpe U1s or by AON 10–27. Accordingly to the pro-
posed antisense mechanism, cotransfection of hnRNPA1
did not affect the splicing rescue induced by the oligonu-
cleotide, indicating that it directly and efficiently blocks
the binding of the splicing factor to the ISS (Figure 3C,
lanes 5–8). On the contrary, the increase in the amount
of the cotransfected splicing factor progressively reduced
the splicing rescue mediated by ExSpe U1 sm21
(Figure 3C, lanes 9–12). Similar results were obtained
with the other two ExSpe U1s, sm2 and sm17 (data not
shown). We also explored the role of endogenous U1
snRNP performing SMN2 minigene splicing assays by
using a U1 snRNA-specific decoy, D1. The D1 plasmid
encodes for a decoy RNA complementary to the 50 tail
of the endogenous U1 snRNA (Figure 3A, left) and was
previously reported to induce skipping of SMN2 E7.35
We cotransfected decoy plasmids along with ExSpe U1s
or AON 10–27 and evaluated the resulting effect on
SMN2 splicing pattern (Figure 3B). The U1 snRNA decoy
(D1) differently affected the rescue efficiency of AON
10–27 and ExSpe U1 sm21. Specifically, D1 reduced the
percentage of SMN2 E7 inclusion induced by the oligonu-
cleotide from 100% inclusion to 25% (Figure 3B, lanes 5
and 6), whereas it has no effect on ExSpe U1 sm21 (lanes
4 and 8). The other two ExSpe U1s, sm2 and sm17, were
also not affected by D1 treatment (data not shown). The
control D3 plasmid (a decoy RNA that contains a
mismatch in the base pairing with the endogenous U1;
Figure 3A, right) did not affect the splicing patterns.
Thus, in contrast to AON 10–27, ExSpe U1s are sensitiveerican Journal of Human Genetics 96, 93–103, January 8, 2015 97
Figure 3. ExSpe U1s Do Not Require the
U1 snRNP and Are Sensitive to hnRNP A1
Overexpression
(A) Schematic representations of the base
pairing between the 50 tail of the U1
snRNA WT and the tail of the RNA U1
decoy (D1) or with the tail of the RNA
U1 mismatch decoy (D3).
(B) HEK293 cells were transfected with pCI
SMN2 plasmid alone or in combination
with plasmids encoding for RNA U1 decoy
(D1), RNA U1 mismatch decoy with a vari-
ation in position þ3 (D3), ExSpe U1 sm21,
or AON 10–27. Total RNA was extracted
and retrotranscribed with randomprimers.
RT-PCR was performed with pCIF Fw and
E8-75 Rev primers. The resulting amplified
products were separated on 2% agarose gel.
The identity of the bands is shown. Band
intensity was quantified with ImageJ soft-
ware and the percentage of exon inclusion
is reported for each lane at the bottom of
the gel, as mean 5 SD of two different
experiments.
(C) SMN2 minigene splicing assay has
been performed in HEK293 cells cotrans-
fected with ExSpe U1 sm21 (lanes 9–12)
or AON 10–27 (lanes 5–8) along with
increasing amount of hnRNPA1 splicing
factor (50-150-250 ng, lanes 10–12 and
6–8, respectively). Total RNAwas extracted
and RT-PCR carried out as described in (B).
The identity of the bands is indicated on
the right of the panel and their intensity
has been quantified with ImageJ software.
The percentage of exon 7 inclusion, ex-
pressed as mean 5 SD of three different
experiments, is reported below the gel.to hnRNPA1 overexpression but do not require the pres-
ence of the endogenous U1 snRNP at the E7 donor splice
site. Therefore, ExSpe U1 mainly replaces the function of
endogenous U1 snRNP in exon definition and does not
act with antisense mechanism on the hnRNPA1-depen-
dent ISS.
Lentiviral Transduction of ExSpe U1s in SMA Type I
Fibroblasts Rescues SMN2 Exon 7 Splicing Pattern and
Increases SMN Protein Levels
To determine the possible therapeutic activity of ExSpe
U1s, we used SMA type I primary fibroblasts that lack
SMN1 and have only two copies of SMN2. Fibroblasts
were infected with lentiviral particles expressing the
three different noncoding ExSpe U1 RNAs or the normal
U1 snRNA WT as control, along with the green fluores-
cent protein (GFP), that was used for the evaluation of
cell transduction efficiency. Lentiviral infection resulted
in the expression of the corresponding ExSpe U1 RNAs
(Figure S6). After lentiviral infection, we evaluated the
percentage of SMN1 and SMN2 E7 inclusion and the
total amount of E7 and DE7 SMN isoforms. In SMA
fibroblasts, lentiviral transduction with the ExSpe U1s
sm2, sm17, and sm21 corrected the splicing defect.98 The American Journal of Human Genetics 96, 93–103, January 8, 2The percentage of SMN2 E7 inclusion increased from
the basal level of ~38% up to ~80%, which corresponds
to the SMN1 value observed in control fibroblasts
(Figure 4A). Infection with U1 snRNA WT did not affect
the splicing pattern. Evaluation of the E7 and DE7 SMN
isoforms showed a ~2.5-fold increase of the E7-corrected
isoform in comparison to untreated cells (Figure 4B).
Consistent with a complex effect on pre-mRNA process-
ing, ExSpe U1s increased also the SMN DE7 isoform,
although to a lesser extent. To assess whether SMN2
splicing rescue in SMA fibroblasts resulted in changes
at the protein level also, we detected the SMN protein
through immunoblot (Figures 4C and 4D). Quantifica-
tion of SMN band intensity showed that the three ExSpe
U1s promoted respectively a ~1.65-, 1.8-, and 1.9-fold in-
crease in the SMN protein in comparison to untreated
SMA fibroblasts. Interestingly, the protein rescue ob-
tained with ExSpe U1s reaches the SMN level present
in control fibroblasts (Figure 4D).
AAV-Mediated Delivery of ExSpe U1 sm21 Enhances
SMN2 Splicing in Transgenic Mice
To evaluate the ExSpe U1 activity in vivo, we decided to
test its effect on SMN2 splicing in mice harboring the015
Figure 4. Lentiviral-Mediated Transduction of ExSpe U1s Res-
cues SMN2 Exon 7 Splicing and Increases Cellular Levels of
SMN Protein
(A) SMA type I fibroblasts (G3813, Coriell Institute) were trans-
duced with lentiviral particles expressing ExSpe U1s sm2, sm17,
The AmSMN2 transgene. We used self-complementary adeno-
associated viruses serotype 9 (scAAV9) encoding for
the U1 snRNA WT (scAAV9-U1WT) or the ExSpe U1
sm21 (scAAV9-ExSpe U1 sm21). Recipient mice of
both sexes were transgenic for SMN2 and hemizygotes
or WT at the mouse Smn locus. We injected four
different SMN2 transgenic mice intraperitoneally at
postnatal day 1 (P1) with scAAV9-ExSpe U1 sm21. As
controls, four animals were treated with scAAV9-
U1WT. The mice were sacrificed 30 days after AAV
administration and total RNA was extracted from brain,
heart, kidney, liver, and skeletal muscle. We analyzed
SMN2 E7 splicing pattern and corresponding E7 and
DE7 isoforms via SMN human-specific primers (Figure 5).
In all tissues analyzed, we observed in mice treated with
ExSpe U1 sm21 a significant increase of the percentage
of SMN2 E7 inclusion and in the amount of the corre-
sponding E7 isoform. In these animals, the percentage
of E7 inclusion increased from ~10% up to ~45%–50%
(Figures 5A–5E, left, lanes 1–4) and the total amount
of E7 isoform showed up to ~2.5- to 3-fold increase.
Interestingly, as observed in stable Flip-In clones and
SMA fibroblasts, the increased levels of the E7 mRNAs
do not associate with decreases in the DE7 mRNA. In
fact, the levels of DE7 remained stable or even slightly
increased in most tissues analyzed (Figure 5, right).
The animals injected with the AAV9-U1WT did notor sm21, as well as U1 WT, with a MOI of 15. Normal fibroblasts
(G3814, Coriell Institute) were used as control. Transduction
efficiency was evaluated through GFP-positive cells at confocal
microscope. Total RNA was extracted and RT-PCR carried out
with a 50-FAM-labeled E6 Fw along with E8-467 Rev primers. The
resulting amplified fragments were digested with DdeI restriction
enzyme to distinguish SMN1 and SMN2 products and run in capil-
lary electrophoresis. The peaks were analyzed with PeakScanner
software and the data are reported as histograms that express the
percentage of exon 7 inclusion as mean 5 SD of three indepen-
dent experiments.
(B) The RNA samples described in (A) were analyzed also by
quantitative TaqMan Assay. Two probes for full-length (E7) or
delta7 (DE7) SMN isoforms were used along with FL-Fw/FL-Rev
and DE7-Fw and DE7-Rev set of primers, as depicted in the
upper part of the panel. 18S RNA was used as normalization
control. The levels of E7 and DE7 in SMA type I fibroblasts were
set to 1. The histograms express the fold changes in SMN E7
or DE7 isoforms in SMA fibroblasts expressing ExSpe U1s or
U1 WT compared to untreated ones and to normal fibroblasts.
***p < 0.001, **p < 0.01; ns, not significant. One-way ANOVA.
(C) SMA type I fibroblasts (Coriell Institute, 3813) were transduced
with lentiviral particles as described in (B). At 72 hr after transduc-
tion, cells were harvested and protein samples loaded on 4%–12%
polyacrylamide gel. The SMN protein was detected by immuno-
blotting in SMA type I fibroblasts (lane 1) and normal control fi-
broblasts (lane 6). SMN protein in SMA fibroblasts treated with
U1 WT or ExSpe U1s sm2, sm17, or sm21 are shown in lanes 2
and 3–5, respectively. The same blot was reprobed with an anti-
body against tubulin as loading control.
(D) The intensity of SMN bands reported in (C) was quantified
with ImageJ software. The histograms indicate the SMN protein
fold increase in comparison to the value of SMA-untreated fibro-
blasts (set to 1), expressed as mean 5 SD of three independent
experiments.
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Figure 5. Effect of ExSpe U1 sm21 in
SMN2 Transgenic Mice
Four different SMN2 transgenic mice (Jack-
son Laboratories, stock 005024) of both
sexes were injected intraperitonelly at P1
with scAAV9-Exspe U1 sm21 (animals 1–
4), four were injected with scAAV9-U1
WT, and four animals were not treated
and have been used as controls. Mice
were sacrificed 4 weeks after AAV adminis-
tration. Organs and tissues including brain
(A), heart (B), kidney (C), liver (D), and
skeletal muscle (E) were harvested and to-
tal RNA was extracted with Trizol reagent.
Left: semiquantitative RT-PCR was carried
out with a set of SMN2-specific primers.
The resulting amplified products were
solved on 1.5% agarose gels. Lanes 1 and
2 show the pattern of splicing of unin-
jected (CNT) and scAAV9-U1WT-injected
mice, as well as the percentage of human
exon 7 (hE7) inclusion expressed as mean
5 SD of the four different mice belonging
to each group. Lanes 3–6 show the single
pattern of splicing of hE7 of the four ani-
mals (mouse 1–4) injected with scAAV9
ExSpe U1 sm21. The identity of the bands
is depicted on the right of the gels and the
percentage of exon inclusion for each lane,
quantified by ImageJ software, is reported.
Right: human-specific SMN TaqMan assay
to detect the levels of E7 or DE7 isoforms.
The levels of E7 or DE7 in the untreated
SMN2 transgenic mouse (group 1, control)
were set to 1. The histograms express the
fold changes of hSMN2 E7 or DE7 isoforms
in group 2 and group 3 animals (treated
with U1 WT or ExSpe U1 sm21, respec-
tively) compared to the untreated control
group. Error bars show standard deviations
(***p < 0.001, **p < 0.01, *p < 0.1; ns, not
significant. One-way ANOVA test).show any change. These data demonstrate that ExSpe
U1 sm21 is able to correct aberrant SMN2 mRNAs
in vivo, suggesting the reliability of this approach for
a possible therapeutic application for SMA.Discussion
We have previously proposed a strategy based on ExSpe
U1s to correct exon-skipping defects. These molecules100 The American Journal of Human Genetics 96, 93–103, January 8, 2015are derivatives of U1 snRNA and
bind by complementarity of their
modified 50 tail to intronic sequences
located at different distances down-
stream of the 50 ss, the canonical U1
snRNP binding position. ExSpe U1s
promote the inclusion of different
defective exons in minigene sys-
tems.12 To establish their therapeutic
potential and to elucidate their
mechanism of action, we have inves-tigated the effect of ExSpe U1s by using SMA cellular
models and mice harboring the SMN2 transgene. The
results we obtained demonstrate that ExSpe U1s are oper-
ative in SMA type I fibroblasts where they promote E7
inclusion and increase SMN protein levels. They are also
effective in vivo, correcting SMN2 aberrant splicing in
mice. Low ExSpe U1 amounts are needed and no toxicity
is apparent. ExSpe U1s show a positive effect on SMN
pre-mRNA processing, which is different from and com-
plements that of AONs.
ExSpe U1s Have a Complex Effect of SMN Pre-mRNA
Processing
To investigate the effect of ExSpe U1s on SMN pre-mRNA
processing, we analyzed the percentage of SMN E7 inclu-
sion as well as the amount of E7, DE7, total mRNAs, and
E2 and E7 pre-mRNAs derived from SMN. Our data indicate
that ExSpe U1s have two main effects on SMN processing,
namely to increase the amount of E7 pre-mRNA substrate
and to promote the correct selection of the defective
exon. In comparison with normal cells, the stable clones
expressing ExSpe U1s from a single chromosome-inte-
grated gene have 1.5-fold more SMN E7 pre-mRNA
intermediate and three times more total SMN mRNA
(Figure 2B). Interestingly, we did not detect any difference
in SMN E2 pre-mRNA intermediate levels between HEK293
Flp-In and stable clones expressing different ExSpe U1s
(Figure 2E), strongly suggesting that the increase in the
SMN E7 pre-mRNA andmRNA does not reflect an enhance-
ment of the transcription. In addition, the increase of E7
pre-mRNA levels does not appear to be related to changes
in splicing kinetics, as in this latter case the total amount
of SMNmRNA should not be affected. Moreover, this effect
is specific for ExSpe U1s, as shown by the fact that the anti-
sense oligonucleotide that targets the corresponding in-
tronic sequences did not increase either the total SMN
mRNA or pre-mRNA transcripts. Analysis of the E7 and
DE7 mRNAs showed that the AON enhances E7 levels at
the expense of DE7, consistent with a ‘‘pure’’ effect on the
splicing decision, as previously reported.31 In contrast,
the higher levels of the pre-mRNA substrate induced by
ExSpe U1s comprise both isoforms, with a more pro-
nounced effect on the E7 mRNAs (Figure 2B). The increase
in E7 andDE7mRNAs is evident in the HEK293 Flp-In cells,
in lentiviral-infected SMA type I fibroblasts (Figure 4B), and
partially in vivo on the SMN2 transgene in AAV-treated
mice (Figures 5A–5E, right). Thus, our results demonstrate
that the ExSpe U1 RNA molecule corrects splicing and
also increases mRNA and pre-mRNA intermediates. The ef-
fect on pre-mRNA processing is probably due to the fact
that, whereas the AON acts as a masking molecule, ExSpe
U1s recruit splicing factors on the defective upstream
exon and diminishes the effect of the mutation. In fact,
we observed that overexpression of hnRNPA1 does not
affect the SMN2 splicing rescuemediated by the oligonucle-
otide (Figure 4). On the contrary, the splicing rescue
promoted by ExSpe U1 was reduced by hnRNPA1 overex-
pression. On the other hand, functional inactivation of
U1 snRNP had no effect on ExSpe U1 but abolished the
AON-dependent rescue (Figure 3B). Thus, AON and ExSpe
U1s act through different mechanisms: AON as an anti-
sense molecule masking the ISS-N1, and ExSpe U1s pro-
moting per se exon definition, most likely by recruiting
factors important for splicing. The effect of ExSpe U1s on
SMN transcript abundance and on the stability of the
corresponding pre-mRNA indicates that, in addition to
their effect on splicing, ExSpe U1s affect other pre-mRNA
processing steps. Actually, U1 snRNP has been shown toThe Ameprotect pre-mRNA premature termination at cryptic polya-
denylation sites within introns7–9 and to regulate trans-
criptional efficiency in model systems.36,37 However, our
30-RACE analysis did not reveal any change in the length
of 30 UTR or usage of alternative polyadenylation sites in
ExSpe U1-expressing cells (Figures 2F and S5), indicating
that ExSpe U1s do not affect SMN polyadenylation.
ExSpe U1s as Therapeutic Tools for Splicing
Modulation in SMA
In addition to the positive effect on pre-mRNA processing,
ExSpe U1s exhibit additional properties regarding an effi-
cient splicing correction. A crucial factor in gene transfer
strategies is the copy number of the therapeutic gene
that every single cell has to reach. For example, at least
100 copies per nucleus of the U7-antisense encoding
gene are required to promote a therapeutic exon skipping
in vivo in Duchenne muscular dystrophy (DMD [MIM
310200]).38 Taking advantage of the well-controlled
HEK293 Flp-In cell system, in the present work we demon-
strate that a single copy of ExSpe U1 sm17 or sm21 gene
leads to the expression of comparable levels of the corre-
spondingmolecule among different stable clones. Interest-
ingly, the very low relative amount of ExSpe U1 versus
endogenous U1 snRNA (<1%) present in stable clones
(Figure S4) corrects with the same efficacy SMN2 E7
splicing and increases total SMN mRNAs (Figure 2B). The
levels of exon inclusion obtained with a single integrated
copy are comparable to the effect obtained after lentiviral
infection of SMA fibroblasts and are in line with other ther-
apeutic strategies.39–42 The significant rescue activity
observed with a single copy of ExSpe U1 might be due to
the strong constitutive ubiquitous U1 promoter or to a
facilitated cotranscriptional recruitment of the resulting
particle on the CTD of RNA polymerase II, as reported for
normal U1 snRNP.37,43
It is important to note that the ExSpe U1-mediated in-
crease of the DE7 isoform we observed in SMA fibroblasts,
in stable HEK293 Flp-In clones and, to a lesser extent, also
in SMN2 transgenic mice is likely to result in an additional
therapeutic advantage because even a modest SMN DE7 in-
crease has been shown to be beneficial in SMA.44 In fact,
although the DE7 isoform contains a strong degradation
signal and is therefore highly unstable,28 it retains some
functional activity in cells.45 Furthermore, expression of
multiple copies of SMN DE7 cDNAs transgene in mice
clearly reduces SMA severity.44
An important feature of ExSpe U1s is that, contrary to
modified U1 snRNA that directly binds to the 50 ss in
SMN246 or in coagulation FVII exon 5,47 they are shown
not to be toxic, at least to cells in culture (Figure S1). Apart
from the invariant gt dinucleotide, the other nucleotides of
mammalian donor splice site sequence differ from the
consensus sequence, particularly in alternatively spliced
exons. It is therefore possible that modified U1s binding
to the 50 ss elicit a toxic effects, affecting the fine regulation
of some critical exons. ExSpe U1s reduce this possibility byrican Journal of Human Genetics 96, 93–103, January 8, 2015 101
targeting nonconserved intronic sequences distant from
the 50 ss. However, future studies will be required to eval-
uate potential off-target effects in vivo in animal models.
As an in vivo proof of ExSpe U1 molecule properties, we
have showed that AAV-mediated administration of ExSpe
U1 in SMN2 transgenic mice recovers E7 inclusion from
~15% up to 50% in brain, heart, kidney, liver, and skeletal
muscle (Figure 2). This result, along with the previous anal-
ysis of FVII deficiency (MIM 227500),47 demonstrates that
ExSpe U1 can be efficiently expressed in vivo in different
mouse tissues (Figure 5) and exert an effect on its natural
human SMN2 target. The Smn-null transgenic mice we
have used have a severe phenotype and survive only a
few days.48 Studies are in progress to establish either the
rescue at the protein level or the effect on survival and
phenotypic rescue in the less severely affected SMN2 trans-
genic mice.
In conclusion, we provide in vitro and in vivo comple-
mentary evidence indicating a strong therapeutic activity
of ExSpe U1s that correct exon skipping in the SMAmodel.
Because this type of splicing error represents a significant
percentage of disease-causing mutations in humans, ExSpe
U1s will have to be explored in relationship with different
pathologies as potential tailored tools aimed at correcting
pre-mRNA splicing defects.Supplemental Data
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